Professor Ian Peake

Clinical Medicine, School of Medicine and Population Health

Emeritus Professor of Molecular Medicine

i.r.peake@sheffield.ac.uk
+44 7785 247 928

+44 114 271 1863 (Fax)

The Medical School

Full contact details

Professor Ian Peake
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries, please contact – iicd-om-operational@sheffield.ac.uk

I joined the University in 1990 as the Sir Edward Mellanby Professor of Molecular Medicine and also hold an Honorary Consultant position with the Sheffield Teaching Hospitals NHS Foundation Trust. I have been Deputy Director of the Division of Genomic Medicine and Director of Research for Medicine.

I am currently focused on my research into inherited bleeding disorders in particular von Willebrands disease.

Research interests

My research interests are inherited disorders of Haemostasis and Thrombosis.

My current research interests focus on von Willebrands Disease. I was a co-applicant on an NIH funded PPG (the Zimmerman Project) with collaborators in Canada and USA. I also co-chaired the EU von Willebrands disease collaborative group which has projects continuing from the EU funded MCMDM-1VWD project which I directed.

Since 2011 I have been a coordinator of an International EU/Iran study of severe Von Willebrands Disease (3WINTERS IPS) sponsored by the a Medical research Charity in Milan Italy.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Tosetto A, Badiee Z, Baghaipour M, Baronciani L, Battle J, Berntorp E, Bodó I, Budde U, Castaman G, Eikenboom JCJ , Eshghi P et al (2020) Bleeding symptoms in patients diagnosed as type 3 von willebrand disease: results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study. Journal of Thrombosis and Haemostasis. View this article in WRRO
Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC , Lillicrap D et al (2018) The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Advances, 2(13), 1585-1594.
Cartwright A, Peake IR, Goodeve AC & Hampshire DJ (2016) In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion.. Haemophilia, 22(5), e484-e487. View this article in WRRO
Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV , Shapiro AD et al (2016) Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood, 127(20), 2481-2488. View this article in WRRO
Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gürsel T , Ingerslev J et al (2013) Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thrombosis and Haemostasis, 110(2), 264-274. View this article in WRRO
Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J , Peake I et al (2013) VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood, 121(12), 2336-2339.
Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P , Peake I et al (2010) von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. Journal of Thrombosis and Haemostasis, 8(9), 1986-1993. View this article in WRRO
PEAKE IR & GOODEVE AC (2010) Genetic testing for von Willebrand disease: the case for. Journal of Thrombosis and Haemostasis, 8(1), 13-16.
Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E , Goudemand J et al (2008) Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 111(7), 3531-3539.
BUDDE U, SCHNEPPENHEIM R, EIKENBOOM J, GOODEVE A, WILL K, DREWKE E, CASTAMAN G, RODEGHIERO F, FEDERICI AB, BATLLE J , PÉREZ A et al (2008) Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Journal of Thrombosis and Haemostasis, 6(5), 762-771.
PEAKE I & GOODEVE A (2007) Type 1 von Willebrand disease. Journal of Thrombosis and Haemostasis, 5(s1), 7-11.
Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R , Budde U et al (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 109(1), 112-121.
EIKENBOOM J, VAN MARION V, PUTTER H, GOODEVE A, RODEGHIERO F, CASTAMAN G, FEDERICI AB, BATLLE J, MEYER D, MAZURIER C , GOUDEMAND J et al (2006) Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. Journal of Thrombosis and Haemostasis, 4(4), 774-782.
TOSETTO A, RODEGHIERO F, CASTAMAN G, GOODEVE A, FEDERICI AB, BATLLE J, MEYER D, FRESSINAUD E, MAZURIER C, GOUDEMAND J , EIKENBOOM J et al (2006) A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). Journal of Thrombosis and Haemostasis, 4(4), 766-773.

Conference proceedings papers

Federici AB, Badiee Z, Baghaipour M-R, Castaman G, Eshghi P, Goudemand J, Hay CRM, Hoorfar H, Karimi M, Keikhaei B , Lassila R et al (2018) Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, Vol. 132(Supplement 1) (pp 2464-2464)

All publications

Journal articles

Cartwright A, Webster SJ, de Jong A, Dirven RJ, Bloomer LDS, AL-Buhairan AM, Budde U, Halldén C, Habart D, Goudemand J , Peake IR et al (2020) Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms. Blood Advances, 4(13), 2979-2990.
Tosetto A, Badiee Z, Baghaipour M, Baronciani L, Battle J, Berntorp E, Bodó I, Budde U, Castaman G, Eikenboom JCJ , Eshghi P et al (2020) Bleeding symptoms in patients diagnosed as type 3 von willebrand disease: results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study. Journal of Thrombosis and Haemostasis. View this article in WRRO
Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC , Lillicrap D et al (2018) The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Advances, 2(13), 1585-1594.
Cartwright A, Peake IR, Goodeve AC & Hampshire DJ (2016) In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion.. Haemophilia, 22(5), e484-e487. View this article in WRRO
Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV , Shapiro AD et al (2016) Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood, 127(20), 2481-2488. View this article in WRRO
Stockley J, Nisar SP, Leo VC, Sabi E, Cunningham MR, Eikenboom JC, Lethagen S, Schneppenheim R, Goodeve AC, Watson SP , Mundell SJ et al (2015) Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PLOS ONE, 10(12), e0143913-e0143913. View this article in WRRO
Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gürsel T , Ingerslev J et al (2013) Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thrombosis and Haemostasis, 110(2), 264-274. View this article in WRRO
Cartwright A, Peake IR & Goodeve AC (2013) Applying in silico analysis to the historically reported VWF exon 42 deletion reveals a probable L1 non-autonomous retrotransposition mediated deletion pathomechanism. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 175-175.
Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J , Peake I et al (2013) VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood, 121(12), 2336-2339.
Schneppenheim R, Budde U, Batlle J, Castaman G, Eikenboom JCJ, Federici AB, Goudemand J, Obser T, Oyen F, Rodeghiero F , Schneppenheim S et al (2012) Intracellular Retention, Enhanced Clearance, and Defective FVIII Binding Are Common Features of Von Willebrand Factor D'-D3 Domain Mutations in Patients with Von Willebrand Disease Type 1 From the European Mcmdm-1VWD Study. Blood, 120(21), 99-99.
Berntorp E, Peake I, Budde U, Laffan M, Montgomery R, Windyga J, Goodeve A, Petrini P, Depka M, Miesbach W , Lillicrap D et al (2012) von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia, 18(s6), 1-13. View this article in WRRO
Hickson N, Hampshire D, Castaman G, Eikenboom J, Rodeghiero F, Peake I, Goodeve A & MCMDM-1VWD and ZPMCB-VWD Study Groups (2011) Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions. Journal of Thrombosis and Haemostasis, 9(3), 603-605. View this article in WRRO
TOSETTO A, RODEGHIERO F, CASTAMAN G, GOODEVE A, FEDERICI AB, BATLLE J, MEYER D, GOUDEMAND J, EIKENBOOM J, SCHNEPPENHEIM R , BUDDE U et al (2011) A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. Haemophilia, 17(1), 165-166.
Hampshire DJ, Burghel GJ, Goudemand J, Bouvet LCS, Eikenboom JCJ, Schneppenheim R, Budde U, Peake IR & Goodeve AC (2010) Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. Haematologica, 95(12), 2163-2165.
Hampshire DJ, Bloomer LD, Al-Buhairan AM, Coyle RE, Vijzelaar RNCP, Lillicrap D, James PD, Eikenboom JCJ, Schneppenheim R, Rodeghiero F , Montgomery RR et al (2010) Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease. Blood, 116(21), 2218-2218.
Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P , Peake I et al (2010) von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. Journal of Thrombosis and Haemostasis, 8(9), 1986-1993. View this article in WRRO
Castaman G, Tosetto A, Cappelletti A, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom JCJ, Schneppenheim R , Budde U et al (2010) Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thrombosis Research, 126(3), 227-231.
PEAKE IR & GOODEVE AC (2010) Genetic testing for von Willebrand disease: the case for. Journal of Thrombosis and Haemostasis, 8(1), 13-16.
Castaman G, Tosetto A, Goodeve A, Federici AB, Lethagen S, Budde U, Batlle J, Meyer D, Mazurier C, Goudemand J , Eikenboom J et al (2010) The impact of bleeding history, von Willebrand factor and PFA-100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. British Journal of Haematology, 151(3), 245-251.
Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F, Goodeve AC, Makris M, Wilde JT, Mumford AD, Watson SP & Mundell SJ (2009) Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood, 113(17), 4110-4113.
Eikenboom JCJ, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W & Mazurier C (2009) Expression of 14 von Willebrand factor mutations identified in patients with type.1 von Willebrand disease from the MCMDM-1VWD study. Journal of Thrombosis and Haemostasis, 7(8), 1304-1312.
HASHEMI SOTEH SMB, ANSON J, INBAL A, PEAKE IR & GOODEVE AC (2008) Re-evaluation of three Israeli families initially diagnosed with type 1 von Willebrand disease in light of the ISTH update on von Willebrand factor pathophysiology and classification. Haemophilia, 14(3), 621-624.
Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E , Goudemand J et al (2008) Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 111(7), 3531-3539.
BUDDE U, SCHNEPPENHEIM R, EIKENBOOM J, GOODEVE A, WILL K, DREWKE E, CASTAMAN G, RODEGHIERO F, FEDERICI AB, BATLLE J , PÉREZ A et al (2008) Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Journal of Thrombosis and Haemostasis, 6(5), 762-771.
Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C , Goudemand J et al (2008) Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). Blood, 111(10), 4979-4985.
PEAKE I & GOODEVE A (2007) Type 1 von Willebrand disease. Journal of Thrombosis and Haemostasis, 5(s1), 7-11.
Soteh MH, Peake IR, Marsden L, Anson J, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J & Goodeve A (2007) Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. Haematologica, 92(4), 550-553.
Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R , Budde U et al (2007) Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 109(1), 112-121.
TOSETTO A, RODEGHIERO F, CASTAMAN G, BERNARDI M, BERTONCELLO K, GOODEVE A, FEDERICI AB, BATLLE J, MEYER D, MAZURIER C , GOUDEMAND J et al (2007) Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). Journal of Thrombosis and Haemostasis, 5(4), 715-721.
Hall AJ, Peake IR & Winship PR (2006) Regulation of the human protein S gene promoter by liver enriched transcription factors. British Journal of Haematology, 135(4), 538-546.
EIKENBOOM J, VAN MARION V, PUTTER H, GOODEVE A, RODEGHIERO F, CASTAMAN G, FEDERICI AB, BATLLE J, MEYER D, MAZURIER C , GOUDEMAND J et al (2006) Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. Journal of Thrombosis and Haemostasis, 4(4), 774-782.
TOSETTO A, RODEGHIERO F, CASTAMAN G, GOODEVE A, FEDERICI AB, BATLLE J, MEYER D, FRESSINAUD E, MAZURIER C, GOUDEMAND J , EIKENBOOM J et al (2006) A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). Journal of Thrombosis and Haemostasis, 4(4), 766-773.
Ludlam CA, Pasi KJ, Bolton-Maggs P, Collins PW, Cumming AM, Dolan G, Fryer A, Harrington C, Hill FGH, Peake IR , Perry DJ et al (2005) A framework for genetic service provision for haemophilia and other inherited bleeding disorders. Haemophilia, 11(2), 145-163.
Laffan M, Brown SA, Collins PW, Cumming AM, Hill FGH, Keeling D, Peake IR & Pasi KJ (2004) The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia, 10(3), 199-217.
Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, Hay CRM, Hill FGH, Laffan M & Peake IR (2004) Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia, 10(3), 218-231.
Johan MF, Bowen DT, Frew ME, Goodeve AC, Wilson GA, Peake IR & Reilly JT (2004) Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 124(6), 843-844.
Abu-Duhier FM, Goodeve AC, Wilson GA, Peake IR & Reilly JT (2003) c-FMSmutational analysis in acute myeloid leukaemia. British Journal of Haematology, 123(4), 749-750.
Care RS, Valk PJM, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WMC, Wilson GA, Gari MA, Peake IR, Lowenberg B & Reilly JT (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121(5), 775-777.
Goodeve AC & Peake IR (2003) The Molecular Basis of Hemophilia A: Genotype-Phenotype Relationships and Inhibitor Development. Seminars in Thrombosis and Hemostasis, 29(1), 023-030.
Abu-Duhier FM, Goodeve AC, Care RS, Gari M, Wilson GA, Peake IR & Reilly JT (2003) Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. British Journal of Haematology, 120(3), 464-470.
Hallworth M, Hyde K, Cumming A & Peake I (2002) The future for clinical scientists in laboratory medicine. Clinical and Laboratory Haematology, 24(4), 197-204.
Abu-Duhier FM, Goodeve AC, Wilson GA, Carr RS, Peake IR & Reilly JT (2002) FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia. Blood, 100(1), 364-364.
Di Bitondo R (2002) Oestrogenic repression of human coagulation factor VII expression mediated through an oestrogen response element sequence motif in the promoter region. Human Molecular Genetics, 11(7), 723-731.
Wilson GA, Pollitt RC, Coelho D, Goodeve AC, Peake IR, Reilly JT & Vandenberghe EA (2001) Routine use of RT-PCR for the detection of TCR gene rearrangement. LEUKEMIA, 15(12), 2010-2010.
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR & Reilly JT (2001) Novel c-fms mutations in acute and chronic myeloproliferative disorders. Blood, 98(11 PART I).
Wilson G, Forrest P, Heppinstall S, Green BN, Goodeve AC, Peake IR, Reilly JT, Porter N & Rees DC (2001) A SECOND CASE OF Hb RENERT [β133(H11)Val → Ala]. Hemoglobin, 25(3), 337-340.
Leuer M, Oldenburg J, Lavergne J-M, Ludwig M, Fregin A, Eigel A, Ljung R, Goodeve A, Peake I & Olek K (2001) Somatic Mosaicism in Hemophilia A: A Fairly Common Event. The American Journal of Human Genetics, 69(1), 75-87.
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR & Reilly JT (2001) Genomic structure of human FLT3: implications for mutational analysis. British Journal of Haematology, 113(4), 1076-1077.
Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR & Reilly JT (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113(4), 983-988.
Goodeve A & Peake I (2001) A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. Best Practice & Research Clinical Haematology, 14(2), 235-240.
Eikenboom JCJ, Ginsburg D, Hilbert L, Mazurier C, Peake IR, Sadler JE, Rodeghiero F & Goodeve AC (2001) A Standard Nomenclature for von Willebrand Factor Gene Mutations and Polymorphisms. Thrombosis and Haemostasis, 85(05), 929-931.
Allen S, Goodeve AC, Peake IR & Daly ME (2001) Endoplasmic Reticulum Retention and Prolonged Association of a von Willebrand's Disease-Causing von Willebrand Factor Variant with ERp57 and Calnexin. Biochemical and Biophysical Research Communications, 280(2), 448-453.
Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR & Reilly JT (2000) Are aberrant BCR-ABL transcripts more common than previously thought?. British Journal of Haematology, 111(4), 1109-1111.
Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR & Reilly JT (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. British Journal of Haematology, 111(1), 190-195.
Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, Ingerslev J, Goodeve AC, Peake IR & Daly ME (2000) A novel von Willebrand disease–causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood, 96(2), 560-568.
Visanji JM, Seargent J, Tahri D, Croft SA, Makris M, Preston FE, Peake IR & Daly ME (2000) Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. British Journal of Haematology, 110(1), 135-138.
Williams I, Bray G, Peake I & Goodeve A (2000) Relationship between Factor VIII Mutation Type and Inhibitor Development in a Cohort of Previously Untreated Patients Treated with Recombinant Factor VIII (Recombinate™). Thrombosis and Haemostasis, 83(06), 844-848.
Goodeve AC, Williams I, Bray GL & Peake IR (2000) Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.. Thromb Haemost, 83(6), 844-848.
Beauchamp NJ, Makris M, Preston FE, Peake IR & Daly ME (2000) Major Structural Defects in the Antithrombin Gene in Four Families with Type I Antithrombin Deficiency. Thrombosis and Haemostasis, 83(05), 715-721.
Allen S, Abuzenadah AM, Blagg JL, Hinks J, Nesbitt IM, Goodeve AC, Gursel T, Ingerslev J, Peake IR & Daly ME (2000) Two novel type 2N von Willebrand disease–causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood, 95(6), 2000-2007.
Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK, Bayliss P, Peake IR, Miller GJ & Preston FE (2000) Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood, 95(6), 1935-1941.
Frost L, Wilson G, Goodeve A, Peake I & Vora A (1999) Intensity of prior therapy influences minimal residual disease (MRD) detection and its clinical significance in childhood lymphoblastic leukaemia (ALL).. BLOOD, 94(10), 203B-203B.
Coughlan TC, Blagg JL, Abulola M, Daly ME, Hampton KK, Makris M, Peake IR & Goodeve AC (1999) Null Alleles Are not a Common Cause of Type 1 von Willebrand Disease in the British Population. Thrombosis and Haemostasis, 82(10), 1373-1375.
Hampton K, Preston FE, Peake I, Goodeve A & Nesbitt IM (1999) A Common Splice Site Mutation Is Shared by Two Families with Different Type 2N von Willebrand Disease Mutations. Thrombosis and Haemostasis, 82(09), 1061-1064.
Beauchamp NJ, Makris M, Preston FE, Peake IR & Daly ME (1999) Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency. THROMBOSIS AND HAEMOSTASIS, 517-518.
Daly ME, Seargent J, Tahri D, Croft SA, Makris M, Preston FE & Peake IR (1999) The 46 allele of the-675 4G/5G dimorphism in the PAI-1 promoter increases thrombotic risk in patients with factor V Leiden. THROMBOSIS AND HAEMOSTASIS, 668-668.
Abuzenadah AM, Gursel T, Ingerslev J, Nesbitt IM, Peake IR & Goodeve AC (1999) Mutational analysis of the von Willebrand factor gene in 27 families from Turkey with von Willebrand disease. THROMBOSIS AND HAEMOSTASIS, 283-283.
Banypersad SM, Makris M, Daly ME, Peake IR & Preston FE (1999) Increased prevalence of compound heterozygosity for the C677T and A1289C dimorphisms in the methylene tetrahydrofolate reductase gene in patients with factor V Leiden and venous thrombosis. THROMBOSIS AND HAEMOSTASIS, 71-71.
Allen S, Abuzenadah AM, Blagg J, Hinks J, Nesbitt IM, Daly ME, Goodeve A, Gursel T, Ingerslev J & Peake IR (1999) CYS788ARG and CYS1225GLY mutations in von Willebrand factor result in combined type 1 and type 2N von Willebrand disease. THROMBOSIS AND HAEMOSTASIS, 686-686.
Allen S, Abuzenadah AM, Daly ME, Goodeve A, Gursel T, Ingerslev J & Peake IR (1999) Arg273Trp mutation in the von Willebrand factor propeptide results in impaired secretion. THROMBOSIS AND HAEMOSTASIS, 687-687.
Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenberghe E, Peake I & Reilly J (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 105(4), 894-900.
Frost L, Wilson G, Goodeve A, Peake I & Vora A (1999) Minimal residual disease clearance in standard risk childhood ALL patients treated on UKALL X and XI protocols.. BRITISH JOURNAL OF HAEMATOLOGY, 105, 80-80.
Hinks JL, Winship PR, Makris M, Preston FE, Peake IR & Goodeve AC (1999) Rapid detection of factor IX gene mutations using conformation sensitive gel electrophoresis.. BRITISH JOURNAL OF HAEMATOLOGY, 105, 36-36.
Hinks JL, Winship PR, Makris M, Preston FE, Peake IR & Goodeve AC (1999) A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. British Journal of Haematology, 104(4), 915-918.
Curtis D, Durkie M, Balac (Morris) P, Sheard D, Goodeve A, Peake I, Quarrell O & Tanner S (1999) A study of Wilson disease mutations in Britain. Human Mutation, 14(4), 304-311.
Frost L, Wilson G, Goodeve A, Peake I & Vora A (1998) Influence of post-induction treatment intensity on rates of minimal residual disease clearance in childhood ALL.. BLOOD, 92(10), 394A-394A.
Leach M, Makris M, Beauchamp NJ, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ & Preston FE (1998) Diagnosis and thrombotic risk in a cohort with genetically confirmed protein S deficiency.. BLOOD, 92(10), 561A-561A.
Gari MA, Goodeve AC, Wilson G, Winship PR, Langabeer S, Linch D, Vandenberghe E, Peake IR & Reilly JT (1998) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia.. BLOOD, 92(10), 592A-593A.
Williams IJ, Peake IR & Goodeve AC (1998) Recombinate PUP mutation study: Examination of the relationship between factor VIII mutations and inhibitor development.. BLOOD, 92(10), 102B-102B.
Beauchamp NJ, Pike RN, Daly M, Butler L, Makris M, Dafforn TR, Zhou A, Fitton HL, Preston FE, Peake IR & Carrell RW (1998) Antithrombins Wibble and Wobble (T85M/K): Archetypal Conformational Diseases With In Vivo Latent-Transition, Thrombosis, and Heparin Activation. Blood, 92(8), 2696-2706.
Beauchamp NJ, Pike RN, Daly M, Butler L, Makris M, Dafforn TR, Zhou A, Fitton HL, Preston FE, Peake IR & Carrell RW (1998) Antithrombins Wibble and Wobble (T85M/K): Archetypal Conformational Diseases With In Vivo Latent-Transition, Thrombosis, and Heparin Activation. Blood, 92(8), 2696-2706.
Vora A, Frost L, Goodeve A, Wilson G, Ireland RM, Lilleyman J, Eden T, Peake I & Richards S (1998) Late Relapsing Childhood Lymphoblastic Leukemia. Blood, 92(7), 2334-2337.
Tagariello G, Belvini D, Are A, Salviato R, Davoli PG, Goodeve AC, Williams I, Peake IR & Traldi A (1998) Genetic carrier state diagnosis of haemophilia: Experience at the Haemophilia Centre in Castelfranco Veneto. THROMBOSIS RESEARCH, 91(3), S63-S64.
Lee CA, Kessler CM, Varon D, Martinowitz U, Heim M & PEAKE IAN (1998) The molecular basis of haemophilia A. Haemophilia, 4(4), 346-349.
Daly ME, Makris M, Preston FE, Peake IR & Beauchamp NJ (1998) A Novel Mutation in Intron K of the PROS1 Gene Causes Aberrant RNA Splicing and Is a Common Cause of Protein S Deficiency in a UK Thrombophilia Cohort. Thrombosis and Haemostasis, 79(06), 1086-1091.
Frost L, Richards S, Goodeve A, Wilson G, Lilleyman J, Eden T, Peake I & Vora A (1998) Late relapsing childhood acute lymphoblastic leukaemia.. BRITISH JOURNAL OF HAEMATOLOGY, 101, 31-31.
Gari MA, Goodeve AC, Wilson G, Winship PR, Vandenberghe E, Peake IR & Reily JT (1998) c-kit mutational analysis in acute and chronic myeloproliferative disorders.. BRITISH JOURNAL OF HAEMATOLOGY, 101, 28-28.
Allen S, Blagg J, Abuzenadah AM, Daly ME, Goodeve A & Peake IR (1998) Pro2063Ser mutation in von Willebrand factor results in impaired intracellular transport and secretion.. BRITISH JOURNAL OF HAEMATOLOGY, 101, 67-67.
Williams IJ, Abuzenadah A, Winship PR, Preston FE, Dolan G, Wright J, Peake IR & Goodeve AC (1998) Precise Carrier Diagnosis in Families with Haemophilia A: Use of Conformation Sensitive Gel Electrophoresis for Mutation Screening and Polymorphism Analysis. Thrombosis and Haemostasis, 79(04), 723-726.
Ludlam CA, Colvin BT, Hill FGH, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Bunschoten EPM, Fijnvandraat K , Kasper CK et al (1998) Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A. Thrombosis and Haemostasis, 79(04), 762-766.
Peake I (1998) Genetic services available for counselling and prenatal diagnosis of haemophilia. Haemophilia, 4(s2), 24-25.
Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR & Miller GJ (1997) Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia. Thrombosis and Haemostasis, 78(06), 1426-1429.
Frost L, Richards S, Goodeve A, Wilson G, Lilleyman J, Eden T, Peake I & Vora A (1997) Late relapsing childhood lymphoblastic leukaemia.. BLOOD, 90(10), 2492-2492.
Frost L, Goodeve A, Wilson G, Peake I, Barker H & Vora A (1997) Clonal stability in late-relapsing childhood lymphoblastic leukaemia. British Journal of Haematology, 98(4), 992-994.
Hop C, Guilliatt A, Daly M, Peake I, vanMourik JA & Pannekoek H (1997) Von Willebrand factor and the Weibel-Palade body. THROMBOSIS AND HAEMOSTASIS, OC691-OC691.
Daly ME, Roberts L, Beauchamp NJ, Makris M, Preston FE & Peake IR (1997) The C677F polymorphism in the methylene tetrahydrofolate reductase gene: Interaction with factor V Leiden in thrombophilia patients. THROMBOSIS AND HAEMOSTASIS, P2154-P2154.
Beauchamp NJ, Rimmer J, Cooper PC, Bayliss P, Makris M, Preston FE, Peake IR & Daly ME (1997) Influence of founder effect and mutations causing borderline phenotypes on the prevalence of antithrombin deficiency in thrombophilic patients. THROMBOSIS AND HAEMOSTASIS, P1764-P1764.
Holliday H, Ellis SP, Peake IR & Winship PR (1997) Two novel polymorphisms in the promoter region of the factor IX gene show differential binding of nuclear factors. THROMBOSIS AND HAEMOSTASIS, P1881-P1881.
Winship PR, Nichols CE, Scattergood A & Peake IR (1997) Association between Msel RFLP genotype and factor IX level in normal females; evidence for a polymorphic oestrogen response element in the factor IX gene promoter. THROMBOSIS AND HAEMOSTASIS, P1882-P1882.
Makris M, Preston FE, Beauchamp NJ, Hampton KK, Daly ME, Cooper P, Bayliss P & Peake IR (1997) Co-inheritance of the 20210A allele of the prothrombin gene increases the thrombotic risk in subjects with familial thrombophilia. THROMBOSIS AND HAEMOSTASIS, SC672-SC672.
Cooper PC, Beauchamp NJ, Daly ME, Bayliss P, Peake IR, Makris M & Preston FE (1997) The prothrombin 20210 G->A variant is associated with increased levels of prothrombin and increased incidence of venous thrombosis. THROMBOSIS AND HAEMOSTASIS, O1546-O1546.
Wilson G, Frost L, Goodeve A, Vandenberghe E, Peake I & Reilly J (1997) BCR-ABL Transcript With an e19a2 (c3a2) Junction in Classical Chronic Myeloid Leukemia. Blood, 89(8), 3064-3064.
Hay CRM, Oilier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FGH, Preston FE & Peake IR (1997) HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A. Thrombosis and Haemostasis, 77(02), 234-237.
Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE & Peake IR (1997) HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party.. Thromb Haemost, 77(2), 234-237.
Hay CRM, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC & Peake IR (1996) HLA class II profile: A determinant of factor VIII inhibitor development in severe haemophilia A.. BLOOD, 88(10), 1306-1306.
Daly ME, Guilliatt AM, Blagg JL & Peake IR (1996) The expression of von Willebrand factor (VWF) in endothelial cell lines ECV304 and EAhy926 following transfection with wild type (WT) and/or mutant VWF expression plasmids.. BLOOD, 88(10), 2951-2951.
Nesbitt IM, Goodeve AC, Preston FE & Peake IR (1996) von Willebrand Factor/Factor VIII Binding Is not Affected by the Arg89Gln Polymorphism in von Willebrand Factor. Thrombosis and Haemostasis, 76(05), 820-821.
Beauchamp NJ, Daly ME, Cooper PC, Noble J, Bayliss P, Makris M, Preston FE & Peake IR (1996) P9 The molecular basis of antithrombin deficiency. Blood Coagulation & Fibrinolysis, 7(7), 734-734.
Goodeve AC, Tagariello G, Chuansumrit A, Preston FE & Peake IR (1996) A rapid and cost effective method for analysis of dinucleotide repeat polymorphisms in the factor VIII gene. Blood Coagulation & Fibrinolysis, 7(7), 672-677.
Beauchamp NJ, Daly ME, Cooper PC, Makris M, Preston FE & Peake IR (1996) Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Blood, 88(5), 1700-1707.
Beauchamp NJ, Daly ME, Cooper PC, Makris M, Preston FE & Peake IR (1996) Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Blood, 88(5), 1700-1707.
Nesbitt IM, Goodeve AC, Guilliatt AM, Makris M, Preston FE & Peake IR (1996) Characterisation of Type 2N von Willebrand Disease Using Phenotypic and Molecular Techniques. Thrombosis and Haemostasis, 75(06), 959-964.
Naylor JA, Nicholson P, Goodeve A, Hassock S, Peake I & Giannelli F (1996) A novel DNA inversion causing severe hemophilia A. BLOOD, 87(8), 3255-3261.
Beauchamp NJ, Daly ME, Cooper PC, Makris M, Preston FE & Peake IR (1996) The molecular basis of protein S deficiency in four unrelated kindred.. BRITISH JOURNAL OF HAEMATOLOGY, 93, 17-17.
Beauchamp NJ, Daly ME, Cooper PC, Makris M, Preston FE & Peake IR (1995) Identification of two protein S gene mutations in two kindred with deficiency of protein S and APC resistance. BLOOD, 86(10), 1426-1426.
Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian HHJ, Negrier C & Vinciguerra C (1995) Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood, 86(6), 2206-2212.
PEAKE I & DALY M (1995) Genetic risk factors for venous thrombosis: laboratory assessment. International Journal of Laboratory Hematology, 17(3), 264-266.
VARADI K, MORITZ B, LANG H, BAUER K, PRESTON E, PEAKE I, RIVARD GE, KEIL B & SCHWARZ HP (1995) A chromogenic assay for activated protein C resistance. British Journal of Haematology, 90(4), 884-891.
Peake I (1995) Molecular Genetics and Counselling in Haemophilia. Thrombosis and Haemostasis, 74(01), 040-044.
PEAKE IAN, SELIGSOHN URI, GITEL S, KITCHEN S & ZIVELIN A (1995) The laboratory diagnosis of haemophilia: Recommendations by the Laboratory Activities Committee of the World Federation of Hemophilia. Haemophilia, 1(3), 159-164.
Peake I (1995) Molecular genetics and counselling in haemophilia.. Thromb Haemost, 74(1), 40-44.
HALL AJ, PEAKE IR & WINSHIP PR (1995) IDENTIFICATION OF MULTIPLE ELEMENTS REGULATING TRANSCRIPTION OF THE PROTEIN-S GENE. THROMBOSIS AND HAEMOSTASIS, 73(6), 1257-1257.
NESBITT IM, GUILLIATT AM, GOODEVE AC, PRESTON FE & PEAKE IR (1995) PHENOTYPIC AND MOLECULAR CHARACTERIZATION OF TYPE-2N VON-WILLEBRAND DISEASE. THROMBOSIS AND HAEMOSTASIS, 73(6), 1169-1169.
SPRAY JRK, NICHOLS C, PEAKE IR & WINSHIP PR (1995) STEROID-HORMONE RESPONSIVE AND LIVER-SPECIFIC ELEMENTS REGULATE TRANSCRIPTION OF THE HUMAN PROTEIN-C GENE. THROMBOSIS AND HAEMOSTASIS, 73(6), 1255-1255.
BEAUCHAMP N, PRESTON FE, DALY M, MAKRIS M & PEAKE IR (1995) COMPARISON OF THE THROMBOTIC RISK IN GROUPS HETEROZYGOUS AND HOMOZYGOUS FOR THE FACTOR-V-G1691A MUTATION CONFERRING APC RESISTANCE. THROMBOSIS AND HAEMOSTASIS, 73(6), 1367-1367.
Naylor JA, Goodeve AC, Nicholson P, Hassock S, Peake IR & Giannelli F (1995) A novel FVIII gene inversion which causes severe haemophilia A. Blood Coagulation & Fibrinolysis, 6(2), 155-155.
Pérez-Casal M, Daly M, Peake I & Batlle J (1995) A case of recessive type 2N von Willebrand's disease due to Arg 53 Trp substitution. American Journal of Hematology, 48(2), 140-140.
PEAKE IAN (1995) The role of gene therapy in haemophilia. Haemophilia, 1(S1), 40-43.
Chuansumrit A, Goodeve A, Sasanakul W, Peake IR, Pintadit P, Hathirat P, Preston FE & Isarangkul P (1995) DNA polymorphisms for carrier detection of hemophilia in Thailand.. Southeast Asian J Trop Med Public Health, 26 Suppl 1, 201-206.
Wood N, Standen GR, Murray EW, Lillicrap D, Holmberg L, Peake IR & Bidwell J (1995) Rapid genotype analysis in type 2B von Willebrand's disease using a universal heteroduplex generator. British Journal of Haematology, 89(1), 152-156.
Hall AJ, Chuansumrit A, Peake IR & Winship PR (1994) A Single Base Pair Deletion in the Promoter Region of the Factor IX Gene Is Associated with Haemophilia B. Thrombosis and Haemostasis, 72(06), 799-803.
SCHWARZ HP, VARADI K, MORITZ B, LANG H, BAUER K, PRESTON E, PEAKE I & RIVARD GE (1994) A CHROMOGENIC ASSAY FOR ACTIVATED PROTEIN-C (APC) RESISTANCE. BLOOD, 84(10), A84-A84.
TUDDENHAM EGD, SCHWAAB R, SEEHAFER J, MILLAR DS, GITSCHIER J, HIGUCHI M, BIDICHANDANI S, CONNOR JM, HOYER LW, YOSHIOKA A , PEAKE IR et al (1994) HEMOPHILIA-A - DATABASE OF NUCLEOTIDE SUBSTITUTIONS, DELETIONS, INSERTIONS AND REARRANGEMENTS OF THE FACTOR-VIII GENE, 2ND EDITION (VOL 22, PG 3511, 1994). NUCLEIC ACIDS RESEARCH, 22(22), 4850-4868.
Beauchamp N, Daly M, Cooper P, Preston FE & Peake I (1994) Rapid two-stage PCR for detecting factor V G1691A mutation. The Lancet, 344(8923), 694-695.
PEAKE I & TUDDENHAM E (1994) A STANDARD NOMENCLATURE FOR FACTOR-VIII AND FACTOR-IX GENE-MUTATIONS AND ASSOCIATED AMINO-ACID ALTERATIONS. THROMBOSIS AND HAEMOSTASIS, 72(3), 475-476.
Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A , Peake IR et al (1994) Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Research, 22(17), 3511-3533.
Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE & Peake IR (1994) High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. British Journal of Haematology, 88(1), 219-222.
Henin C, Makris M, Brown J, Peake IR & Preston EF (1994) Peripheral mononuclear cells of haemophiliacs with chronic liver disease are infected with replicating hepatitis C virus. British Journal of Haematology, 87(1), 215-217.
Goodeve AC, Preston FE & Peake IR (1994) Factor VIII gene rearrangements in patients with severe haemophilia A. The Lancet, 343(8893), 329-330.
Goodeve AC, Chuansumrit A, Sasanakul W, Isarangkura P, Preston FE & Peake IR (1994) A comparison of the allelic frequencies of ten DNA polymorphisms associated with factor VIII and factor IX genes in Thai and Western European populations. Blood Coagulation & Fibrinolysis, 5(1), 29-36.
Peake I & Tuddenham E (1994) A Standard Nomenclature for Factor VIII and Factor IX Gene Mutations and Associated Amino Acid Alterations. Thrombosis and Haemostasis, 72(03), 475-476.
Pérez-Casal M, Daly M & Peake A (1993) A de novo mutation in exon 28 of the von Willebrand factor gene in a patient with type IIA von Willebrand's disease coincides with an Mbol polymorphism in the von Willebrand factor pseudogene. Human Molecular Genetics, 2(12), 2159-2161.
Peake I (1993) Detection of carriers and prenatal diagnosis of bleeding disorders.. The Southeast Asian journal of tropical medicine and public health, 24 Suppl 1, 37-40.
PEREZCASAL M, DALY M & PEAKE I (1993) MBO-I POLYMORPHISM IN THE VON-WILLEBRAND-FACTOR PSEUDOGENE. THROMBOSIS AND HAEMOSTASIS, 69(6), 1178-1178.
HALL A, PEAKE I & WINSHIP PR (1993) SINGLE-BASE CHANGES IN C/EBP BINDING-SITE WITHIN THE FACTOR-IX PROMOTER AND THEIR RELATIVE EFFECTS ON TRANSCRIPTION LEVELS. THROMBOSIS AND HAEMOSTASIS, 69(6), 767-767.
WINSHIP PR & PEAKE I (1993) TESTOSTERONE-INDUCED RECOVERY OF FACTOR-IX TRANSCRIPTION IN PATIENTS WITH THE HEMOPHILIA-B LEYDEN PHENOTYPE. THROMBOSIS AND HAEMOSTASIS, 69(6), 847-847.
PEAKE I, THOMSON J, POLLER L, CROWE W & GOODEVE A (1993) THE FACTOR-VII ARG-353 GLN POLYMORPHISM AS A PREDICTOR OF HIGH PLASMA FACTOR-VII LEVELS IN A NORMAL POPULATION. THROMBOSIS AND HAEMOSTASIS, 69(6), 624-624.
Winship PR, Nichols CE, Chuansumrit A & Peake IR (1993) An MseI RFLP in the 5’flanking region of the factor IX gene: its use for haemophilia B carrier detection in Caucasian and Thai populations. British Journal of Haematology, 84(1), 101-105.
Peake IR, Lillicrap DP, Boulyjenkov V, Bri??t E, Chan V, Ginter EK, Kraus EM, Ljung R, Mannucci PM, Nicolaides K & Tuddenham EGD (1993) Report of a joint WHO/WFH meeting on the control of haemophilia. Blood Coagulation & Fibrinolysis, 4(2), 313-344.
Peake I (1993) Arthur Leslie Bloom. Thrombosis and Haemostasis, 69(03), 216-216.
PEAKE I (1993) BLOOM,ARTHUR,LESLIE - OBITUARY. THROMBOSIS AND HAEMOSTASIS, 69(3), 216-216.
Peake IR, Lillicrap DP, Boulyjenkov V, Briet E, Chan V, Ginter EK, Kraus EM, Ljung R, Mannucci PM & Nicolaides K (1993) Haemophilia: strategies for carrier detection and prenatal diagnosis.. Bulletin of the World Health Organization, 71(3-4), 429-458.
Peake I (1992) Registry of DNA Polymorphisms Within or Close to the Human Factor VIII and Factor IX Genes. Thrombosis and Haemostasis, 67(02), 277-280.
Kasper C, Mannucci P, Bulyzhenkov V, Brettler D, Chuansumrit A, Heijnen L, Isarankura P, Kernoff P, Peake I, Rickard K , Schulman S et al (1992) Hemophilia in the 1990s: Principles of Management and Improved Access to Care. Seminars in Thrombosis and Hemostasis, 18(01), 1-10.
RICKLES F, HOYER L, JOIST H, PEAKE I, ALEDORT L, KASPER C, LUSHER J, THOMPSON A, KIM H & BRIET E (1991) INHIBITOR DETECTION - ASSAYS, THEIR VARIATION, SIGNIFICANCE AND INTERPRETATION - IMMUNOCHEMISTRY OF FACTOR-VIII-C AND FACTOR-IX-C INHIBITORS - EPITOPES AND MECHANISM OF ACTION - DISCUSSION. BLOOD COAGULATION & FIBRINOLYSIS, 2, 17-20.
THOMPSON A, LOZIER J, BRIET E, DIMICHELE D, HOOTS K, KASPER C, LUSHER J, ALEDORT L, PEAKE I, GUERIN V & HOYER L (1991) FACTOR-IX INHIBITORS IN HEMOPHILIA-B PATIENTS, THEIR INCIDENCE AND PROSPECTS FOR DEVELOPMENT WITH HIGH-PURITY FACTOR-IX PRODUCTS - ANAMNESTIC RESPONSE FOLLOWING INFUSION OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES (APCC) IN HEMOPHILIA-A PATIENTS WITH INHIBITORS - DISCUSSION. BLOOD COAGULATION & FIBRINOLYSIS, 2, 59-62.
ALEDORT L, HOOTS K, ROBERTS H, LUSHER J, HOYER L, GILES A, PENNER J, KISKER T, JOIST H, BLANCHETTE V & PEAKE I (1991) FACTOR-VIII INHIBITORS IN A HEMOPHILIC POPULATION TREATED WITH LOW AND HIGH-PURITY FVIII CONCENTRATES - DISCUSSION. BLOOD COAGULATION & FIBRINOLYSIS, 2, 25-30.
Tuddenham EGD, Cooper DN, Gitschier J, Higuchi M, Hoyer LW, Yoshioka A, Peake IR, Schwaab R, Olek K, Kazazian HH , Lavergne JM et al (1991) Haemophilia A: database of ncleotide substituttions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Research, 19(18), 4821-4833.
Bowen DJ, Webb CE, Peake IR & Bloom AL (1991) Aatll polymorphism in von Willebrand factor gene at codon 471. Nucleic Acids Research, 19(11), 3159-3159.
Standen GR & Peake IR (1991) The molecular biology of von Willebrand's disease.. Q J Med, 79(289), 381-389.
Murray EW, Giles AR, Bridge PJ, Peake IR & Lillicrap DP (1991) Cosegregation of von Willebrand factor gene polymorphisms and possible germinal mosaicism in type IIB von Willebrand disease. Blood, 77(7), 1476-1483.
Kasper CK, Mannucci PM, Bulyzhenkov V, Brettler DB, Chuansumrit A, Heijnen L, Isarankura P, Kemoff PBA, Peake I, Rickard KA , Schulman S et al (1991) Haemophilia in the 1990s: Report of a Joint Meeting of the World Health Organization and World Federation of Hemophilia. Vox Sanguinis, 61(3), 221-224.
Peake I & Winship P (1991) What is a polymorphism? [letter; comment]. Blood, 78(1), 250-250.
Wilson GA, Vandenberghe EA, Pollitt RC, Rees DC, Goodeve AC, Peake IR & Reilly JT () Are aberrant BCR-ABL transcripts more common than previously thought?. British Journal of Haematology, 111(4), 1109-1111.
Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR & Reilly JT () FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. British Journal of Haematology, 111(1), 190-195.
Peake L () Current Status of Gene Therapy in Haemophilia A and B. Arzneimittelforschung, 49(02), 163-165.
Bowen DJ, Thomas P, Webb CE, Bignell P, Peake IR & Bloom AL () Facile and rapid analysis of three DNA polymorphisms within the human factor IX gene using the polymerase chain reaction. British Journal of Haematology, 77(4), 559-560.
() The Molecular Biology of von Willebrand's Disease. QJM: An International Journal of Medicine.

Chapters

Goodeve AC & Peake IR () Laboratory Analysis of Von Willebrand Disease: Molecular Analysis, Quality in Laboratory Hemostasis and Thrombosis (pp. 204-215). John Wiley & Sons, Ltd
Lillicrap D, Rodeghiero F & Peake I () Clinical, Laboratory, and Molecular Markers of Type 1 von Willebrand Disease, Von Willebrand Disease (pp. 127-136). Wiley-Blackwell

Conference proceedings papers

Baronciani L, Budde U, Stufano F, Peyvandi F, Goodeve A, Schneppenheim R, Badiee Z, Baghaipour MR, Battle J, Berntorp E , Bodo I et al (2019) EVALUATION OF THE VON WILLEBRAND FACTOR (VWF) INHIBITOR IN A LARGE COHORT OF EUROPEAN AND IRANIAN PATIENTS PREVIOUSLY DIAGNOSED WITH TYPE 3 VON WILLEBRAND DISEASE (VWD3) ENROLLED INTO THE 3WINTER-IPS PROJECT. HAEMATOLOGICA, Vol. 104 (pp 24-24)
Federici AB, Badiee Z, Baghaipour M-R, Castaman G, Eshghi P, Goudemand J, Hay CRM, Hoorfar H, Karimi M, Keikhaei B , Lassila R et al (2018) Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, Vol. 132(Supplement 1) (pp 2464-2464)
Tosetto A, Christopherson PA, Eikenboom JCJ, Grabell J, James PD, Montgomery RR, Peake I, Silva M & Investigators ZP (2018) Bleeding Patterns in Type I VWD in Effect of VWF Levels: An Individual Participant Data Meta-Analysis of Three Cohorts. Blood, Vol. 132(Supplement 1) (pp 1180-1180)
Tosetto A, Badiee Z, Baghaipour M-R, Baronciani L, Battle J, Berntorp E, Bodó I, Budde U, Castaman G, Eikenboom JCJ , Eshghi P et al (2018) Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, Vol. 132(Supplement 1) (pp 2465-2465)
Baronciani L, Peyvandi F, Goodeve A, Schneppenheim R, Badiee Z, Baghaipour M-R, Battle J, Berntorp E, Bodó I, Budde U , Cairo A et al (2018) Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, Vol. 132(Supplement 1) (pp 1184-1184)
Webster SJ, Cartwright A, Hampshire DJ, Peake IR, Goodeve AC & EU-VWD and ZPMCB-VWD study groups (2015) High resolution microscopic characterisation of VWF biosynthesis, storage and secretion in type 1 VWD patients with large in-frame VWF deletions. Journal of Thrombosis and Haemostasis, Vol. 13(Suppl. 2) (pp 23-23), 20 June 2015 - 25 June 2015.
Mufti A, Goodeve A, Peake I, Hampshire D & EU-VWD and ZPMCB-VWD study groups (2015) Single nucleotide variants c.2365A>G and c.2385T>C are associated with increased VWF plasma levels through an effect on mRNA half-life. Journal of Thrombosis and Haemostasis, Vol. 13(Suppl. 2) (pp 251-251), 20 June 2015 - 25 June 2015.
Dsouza MM, Webster SJ, McMaster J, Cartwright A, Budde U, Peake IR, Goodeve AC, Hampshire DJ & EU-VWD and ZPMCB-VWD study groups (2015) Missense mutations located in the von Willebrand factor (VWF) D1 domain cause quantitative VWF deficiency through impairment of VWF packaging into storage organelles. Journal of Thrombosis and Haemostasis, Vol. 13(Suppl. 2) (pp 508-508), 20 June 2015 - 25 June 2015.
Cartwright A, Webster SJ, Jacobi PM, Hickson N, Budde U, Peake IR, Goodeve AC, Haberichter SL, Hampshire DJ & EU-VWD and ZPMCB-VWD study groups (2015) Functional characterisation of a novel splice mutation, c.7887+2T>A, associated with type 1 von Willebrand disease. Journal of Thrombosis and Haemostasis, Vol. 13(Suppl. 2) (pp 505-505), 20 June 2015 - 25 June 2015.
Webster SJ, Hampshire DJ, Schneppenheim R, Bellissimo D, James P, Theophilus B, Peake IR, Goodeve AC & EU-VWD and ZPMCB-VWD study groups (2015) Detection of large exonic and intergenic deletions in the VWF locus of VWD patients using array comparative genomic hybridisation (ACGH). Journal of Thrombosis and Haemostasis, Vol. 13(Suppl. 2) (pp 126-126), 20 June 2015 - 25 June 2015.
Cartwright A, Christopherson PA, Perry CL, Haberichter SL, Hampshire D, Peake IR, Goodeve A, Montgomery RR, Bellissimo DB & Zimmerman Program Investigators (2014) Characterization and expression of an in-frame exon 33-34 deletion causing type 1 VWD. Blood, Vol. 124
Goodeve AC, Hampshire D, Batlle J, Budde U, Castaman G, Eikenboom HCJ, Federici AB, Schneppenheim R & Peake IR (2013) Re-evaluation of sequence variation in type 1 von Willebrand disease in the MCMDM-1VWD cohort. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 11 (pp 413-414)
Mufti A, Lillicrap D, Peake IR, Goodeve AC & Hampshire D (2013) Investigation of the effect of CLEC4M on plasma von Willebrand factor level in the general population. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 11 (pp 552-553)
Cartwright A, Hampshire DJ, Bloomer L, Al-Buhairan AM, Vijzelaar NCP, Budde U, Eikenboom HCJ, Schneppenheim R, Peake IR & Goodeve AC (2013) Characterisation of large in-frame deletions contributing to type 1 VWD pathogenesis in the MCMDM-1VWD study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 11 (pp 117-118)
Alyami NH, Hampshire D, Goudemand J, Castaman G, Federici AB, Cartwright A, Peake IR & Goodeve AC (2013) Previously missed mutations in the MCMDM-1VWD type 1 von Willebrand disease study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 11 (pp 415-415)
Hampshire DJ, Abuzenadah AM, Al-Shammari NS, Eckert M, Coyle RE, Al-Buhairan AM, Messenger SL, Gursel T, Ingerslev J, Peake IR & Goodeve AC (2011) Characterisation of von Willebrand disease mutational spectrum in a Turkish patient cohort. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 9 (pp 914-914)
Alyami NH, Hampshire DJ, Goudemand J, Castaman G, Federici AB, Peake IR, Goodeve AC, Grp EU-VWDS & Grp ZPMCB-VWDS (2011) Missing mutation in type 1 von Willebrand disease in the MCMDM-1 VWD study. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 9 (pp 914-914)
Hampshire DJ, Cartwright A, Bloomer LD, Al-Buhairan AM, Vijzelaar RNCP, Habart D, Hill FGH, Rodeghiero F, Budde U, Eikenboom JCJ , Peake IR et al (2011) Copy number variation is a significant contributor to type 1 VWD pathogenesis in the EU MCMDM-1VWD cohort. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 9 (pp 55-56)
Hampshire DJ, Bloomer LD, Al-Buhairan AM, Coyle RE, Vijzelaar RNCP, Lillicrap D, James PD, Eikenboom JCJ, Schneppenheim R, Rodeghiero F , Montgomery RR et al (2010) Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease.. BLOOD, Vol. 116(21) (pp 913-913)
Flood VH, Kautza BC, Miller CA, Branchford BR, Gill JC, Haberichter SL, Morateck PA, Christopherson PA, Perry CL, Friedman KD , Bellissimo DB et al (2007) Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing.. Blood, Vol. 110(11) (pp 714-714)
Chuansumrit A, Sasanakul W, Williams I, Goodeve A, Kadegasem P & Peake I (2004) Comparison of Phenotypic Assessment and Mutation Detection in the Diagnosis of Carrier State in Hemophilia: Identification of 10 Novel Mutations.. Blood, Vol. 104(11) (pp 4020-4020)
Eikenboom JCJ, van Marion V, Putter H, Garcia EBG, Peake I, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J , Meyer D et al (2003) Analysis of cosegregation of type 1 Von Willebrands disease phenotype and von Willebrand factor gene haplotypes in the European Multicenter MCMDM-1VWD study.. BLOOD, Vol. 102(11) (pp 90A-90A)
Goodeve A, Walker M, Peake I, Rodeghiero F, Castaman G, Federici A, Batlle J, Meyer D, Eikenboom J, Schneppenheim R , Ingerslev J et al (2003) Contribution of ABO blood group to type 1 von Willebrand disease in patients entered in the multicentre MCMDM-1VWD study.. BLOOD, Vol. 102(11) (pp 91A-91A)
Lester WA, Bowen DJ, Cumming A, Collins PW, Watson P, Keeney S, Enayat MS, Keeling D, Pasi KJ, Bolton-Maggs P , Liesner R et al (2003) Variable phenotypic penetrance of von Willebrand factor gene Y1584C heterozygosity in type 1 von Willebrand disease families and its association with enhanced in vitro susceptibility to ADAMTS 13 mediated proteolysis.. BLOOD, Vol. 102(11) (pp 311A-311A)
Hashemi MB, Inbal A, Peake IR, Mikris M, Hampton E & Goodeve AC (2002) Mutational analysis in five families with type 1 von Willebrand disease. BLOOD, Vol. 100(11) (pp 69B-69B)
Care RS, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort W, Valk PJM, Lowenberg B, Wilson GA, Gari MA, Peake IR & Reilly JT (2002) Incidence and prognosis of c-kit and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.. BLOOD, Vol. 100(11) (pp 746A-746A)
Sadler JE, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A & Mannucci PM (2000) Impact, Diagnosis and Treatment of von Willebrand Disease. Thrombosis and Haemostasis, Vol. 84(08) (pp 160-174)
Hop C, Guilliatt A, Daly M, de Leeuw HP, Brinkman H-JM, Peake IR, van Mourik JA & Pannekoek H (2000) Assembly of Multimeric von Willebrand Factor Directs Sorting of P-Selectin. Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 20(7) (pp 1763-1768)
Frost L, Wilson G, Goodeve A, Gerrard M, Snowden J, Peake I & Vora A (1999) Relapsing precursor B-ALL presenting as CD-10 positive isolated extramedullary lymphoma.. BLOOD, Vol. 94(10) (pp 219B-219B)
Coughlan TC, Goodeve AC, Hampton KK, Makris M & Peake IR (1998) Null alleles are not a common cause of type 1 vonWillebrand's disease. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 102(1) (pp 15-15)
Nesbitt IM, Goodeve AC, Hampton KK, Preston FE & Peake IR (1998) Two unrelated families with different type 2N VWD mutations share a common splice site mutation.. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 101 (pp 87-87)
Abuzenadah AM, Goodeve AC, Gursel T, Daly ME, Ingerslev J & Peake IR (1998) Mutations in the pro-peptide of VWF causing type 1 and type 3 VWD.. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 101 (pp 67-67)
Williams IJ, Peake IR, Goodeve AC & Grp RPUPS (1998) Recombinate PUP mutation study: Relationship between factor VIII mutation and inhibitor development. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 101 (pp 84-84)
Abuzenadah AM, Goodeve AC, Ingerslev J, Gursel T & Peake IR (1997) Mutations within the vWF gene resulting in type 1 and type 3 vWD in consanguineous families. THROMBOSIS AND HAEMOSTASIS (pp P2667-P2667)
Ollier W, Hay CRM, Pepper L, Cumming A, Keeney S, Goodeve AC, Preston FE, Colvin BT, Hill FGH & Peake IR (1997) HLA class II profile: A determinant of inhibitor development in severe haemophilia A. THROMBOSIS AND HAEMOSTASIS (pp P2657-P2657)
Nesbitt IM, Goodeve AC, Daly ME, Hampton KK, Makris M, Preston FE & Peake IR (1997) Mutation at Arg611 in the von Willebrand factor gene results in unclassifiable type 2 von Willebrand disease. THROMBOSIS AND HAEMOSTASIS (pp P2665-P2665)
Naylor JA, Nicholson P, Goodeve A, Hassock S, Peake I & Giannelli F (1996) A novel DNA inversion causing severe hemophilia A. Blood, Vol. 87(8) (pp 3255-3261)
GOODEVE AC, PRESTON FE & PEAKE IR (1995) A RAPID AND COST-EFFECTIVE METHOD FOR ANALYSIS OF DINUCLEOTIDE REPEAT POLYMORPHISMS IN THE FACTOR-VIII GENE. THROMBOSIS AND HAEMOSTASIS, Vol. 73(6) (pp 1221-1221)
Peake IR (1995) The molecular biology of haemophilia. HEREDITARY DISEASES AND BLOOD TRANSFUSION, Vol. 30 (pp 3-9)
Higins KS, Goodeve AC, Yeo WW, Morice AH & Peake IR (1992) Improved detection of the insertion/deletion polymorphism of the ACE gene and relationship to serum ACE activity in a normotensive U.K. population. British Journal of Clinical Pharmacology, Vol. 34(2)

Posters

Federici AB, Peyvandi F, Budde U, Castaman G, Eikenboom J, Eshghi P, Goodeve A, Goodemand J, Hoorfar H, Karimi M , Peake IR et al (2015) New insights into type 3 von Willebrand disease: the type 3 von Willebrand disease international registries and inhibitor prospective study (3WINTERS-IPS) project update.

Teaching interests: I teach at the postgraduate level.

Professional activities and memberships

I was a partner of the Health and Care Professions Council (HCPC) as a Clinical Scientist, I was also Registration Assessor for HCPC and for the Association of Clinical Scientists.

I am a past President of the International Society on Thrombosis and Haemostasis (ISTH Congress Birmingham 2003) and Chair of the ISTH Council (2006-2008). I am a past Council member of the British Society for Haemostasis and Thrombosis and the European Association for Haemophilia and Allied Disorders. I was also a member of the Education Committee of the European Haematology Association until 2012.